References
Zaret BL, Wackers FJ. Nuclear cardiology (1). N Engl J Med 1993;329:775–83.
Zaret BL, Wackers FJ. Nuclear cardiology (2). N Engl J Med 1993;329:855–63.
Jain D. 99mTechnetium labeled myocardial perfusion imaging agents. Sernin Nucl Med 1999;29:221–36.
Wackers FJ. Science, art, and artifacts: how important is quantification for the practicing physician interpreting myocardial perfusion studies? J Nucl Cardiol 1994;1:S109–17.
Strauss HW, Nunn A, Linder K. Nitroimidazoles for imaging hypoxic myocardium. J Nucl Cardiol 1995;2:437–45.
Sinusas AJ. New approaches to myocardial imaging with hypoxia markers. In: Iskandrian AE, Verani MS, editors. New Developments in Cardiac Nuclear Imaging. 1st ed. New York: Futura; 1998. p. 203–18.
Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884–8.
Bax JJ, Visser FC, Blanksma PK, et al. Comparison of myocardial uptake of fluorine-18-fluorodeoxyglucose imaged with PET and SPECT in dyssynergic myocardium. J Nucl Med 1996;37:1631–6.
Sandler MP, Patton JA. Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography: an alternative for determining myocardial viability. J Nucl Cardiol 1996;3:342–9.
Go RT, MacIntyre WJ, Cook SA, Neumann DR, Brunken RC, Saha GB, et al. The incidence of scintigraphically viable and nonviable tissue by rubidium-82 and fluorine-18-fluorodeoxyglucose positron emission tomographic imaging in patients with prior infarction and left ventricular dysfunction. J Nucl Cardiol 1996;3:96–104.
Camici P, Araujo L, Spinks T, Lammertsma A, Kaski J, Shea M. Increased uptake of 18-F-fluorodeoxyglucise in postischemic myocardium of patients with exercise induced angina. Circulation 1986;74:81–8.
Abramson B, Ruddy T, deKemp R, Laramee L, Marquis J, Beanlands R. Stress perfusion/metabolism imaging: a pilot study for a potential new approach to the diagnosis of coronary disease in women. J Nucl Cardiol 2000;7:205–12.
Depre C, Taegtmeyer H. Glucose for the heart. Circulation 1999;99:578–88.
Sun D, Nguyen N, Degrado T, Schwaiger M, Brosius F. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT 4 to the plasma membrane of cardiac myocytes. Circulation 1994;89:793–8.
Young LH, Renfu Y, Russell R, Hu X, Caplan M, Ren J, et al. Low-flow ischemia leads to translocation of canine heart GLUT-4 and GLUT-1 glucose transporters to the sarcolemma in vivo. Circulation 1997;95:415–22.
McNulty PH, Luba MC. Transient ischemia induces regional myocardial glycogen synthase activation and glycogen synthesis. Am J Physiol 1995;268:H364–70.
McNulty PH, Jagasia D, Cline G, Ng C, Whiting J, Garg P, et al. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation 2000;101:917–23.
McNulty PH, Sinusas A, Shi C, Dione D, Young L, Cline G, et al. Glucose metabolism distal to a critical coronary stenosis in a canine model of low-flow myocardial ischemia. J Clin Invest 1996;98:62–9.
Runnman EM, Lamp ST, Weiss JN. Enhanced utilization of exogenous glucose improves cardiac function in hypoxic rabbit ventricle without increasing total glycolytic flux. J Clin Invest 1990;86:1222–33.
Lewandowski ED, White LT. Pyruvate dehydrogenase influences postischemic heart function. Circulation 1995;91:2071–9.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jain, D., McNulty, P.H. Exercise-induced myocardial ischemia: Can this be imaged with F-18-fluorodeoxyglucose?. J Nucl Cardiol 7, 286–288 (2000). https://doi.org/10.1016/S1071-3581(00)70020-1
Issue Date:
DOI: https://doi.org/10.1016/S1071-3581(00)70020-1